Katherine Conant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katherine Conant has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Adam Caccavano
Section on Cellular and Synaptic Physiology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health
9 shared publications Matthew Amontree
Department of Neuroscience, Georgetown University School of Medicine, Washington, USA
9 shared publications- Stefano Vicini
Interdisciplinary Program in Neuroscience, Georgetown University Medical Center
8 shared publications - P. Lorenzo Bozzelli
Department of Brain and Cognitive Sciences, Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, USA
7 shared publications - Ismary Blanco
Vanderbilt University Medical Center
5 shared publications - Kathleen A. Maguire-Zeiss
Department of Neuroscience, Georgetown University School of Medicine, Georgetown University Medical Center, Washington, DC, USA 20007
5 shared publications
Latest Publications
- Open Access
5-HT2A receptor deletion is associated with reduced hippocampal parvalbumin levels and anxiety-like behavior in BALB/c mice
The serotonin 2A receptor (5-HT2AR) is a target of drugs used to treat anxiety and mood disorders, yet whether endogenous 5-HT2AR signaling constrains or promotes anxiety, and how the 5-HT2AR affects cell populations linked to anxiety, is not fully resolved. Acute 5-HT2AR agonism is anxiolytic and acts through the activation of ventral hippocampal parvalbumin-expressing interneurons. Here we report that constitutive deletion of the 5-HT2AR in male and female BALB/c mice is associated with robust anxiety-like and repetitive behavior across multiple paradigms. Unbiased proteomic analysis of male knockout hippocampal tissue revealed substantially reduced levels of parvalbumin (PV), a proxy of their activity. Consistent with the intense metabolic demands of fast spiking interneurons, proteins supporting energy metabolism were also downregulated, including those related to oxidative phosphorylation and the electron transport chain, glycolysis and the tricarboxylic acid cycle, together with the cytoplasmic ribosome. In terms of how reduced 5-HT2AR signaling could lead to reduced PV expression, we examined key perineuronal net (PNN) components. The PNN constituents aggrecan and HAPLN1 were not significantly changed, whereas the link protein, HAPLN4 was substantially reduced. In a separate cohort, 7 days following a single dose of the selective 5-HT2AR agonist, 25CN-NBOH, many of the same energy metabolism proteins were shifted in the opposite direction. Together these findings indicate that constitutive loss of 5-HT2AR signaling is associated with coordinated reductions in parvalbumin and in the biosynthetic and bioenergetic machinery that supports fast-spiking activity, without a generalized loss of perineuronal net structural components.
Open Access5-HT2A receptor deletion is associated with reduced hippocampal parvalbumin levels and anxiety-like behavior in BALB/c mice
The serotonin 2A receptor (5-HT2AR) is a target of drugs used to treat anxiety and mood disorders, yet whether endogenous 5-HT2AR signaling constrains or promotes anxiety, and how the 5-HT2AR affects cell populations linked to anxiety, is not fully resolved. Acute 5-HT2AR agonism is anxiolytic and acts through the activation of ventral hippocampal parvalbumin-expressing interneurons. Here we report that constitutive deletion of the 5-HT2AR in male and female BALB/c mice is associated with robust anxiety-like and repetitive behavior across multiple paradigms. Unbiased proteomic analysis of male knockout hippocampal tissue revealed substantially reduced levels of parvalbumin (PV), a proxy of their activity. Consistent with the intense metabolic demands of fast spiking interneurons, proteins supporting energy metabolism were also downregulated, including those related to oxidative phosphorylation and the electron transport chain, glycolysis and the tricarboxylic acid cycle, together with the cytoplasmic ribosome. In terms of how reduced 5-HT2AR signaling could lead to reduced PV expression, we examined key perineuronal net (PNN) components. The PNN constituents aggrecan and HAPLN1 were not significantly changed, whereas the link protein, HAPLN4 was substantially reduced. In a separate cohort, 7 days following a single dose of the selective 5-HT2AR agonist, 25CN-NBOH, many of the same energy metabolism proteins were shifted in the opposite direction. Together these findings indicate that constitutive loss of 5-HT2AR signaling is associated with coordinated reductions in parvalbumin and in the biosynthetic and bioenergetic machinery that supports fast-spiking activity, without a generalized loss of perineuronal net structural components.
- Open Access
- 29 October 2026
- Published by Springer Nature in Scientific Reports
4-methylumbelliferone attenuates amyloid pathology and learning deficits in the APP/PS1 mouse model
- 29 October 2026
- Published by Springer Nature in Scientific Reports
Open Access4-methylumbelliferone attenuates amyloid pathology and learning deficits in the APP/PS1 mouse model
- Open Access
4-methylumbelliferone attenuates amyloid pathology and learning deficits in the APP/PS1 mouse model
4-Methylumbelliferone (4-MU) inhibits hyaluronic acid (HA) synthesis and is currently approved in Europe for biliary spasm. 4-MU administration reduces perineuronal nets (PNNs), and enzymatic degradation of PNNs in mouse models of Alzheimer’s disease (AD) attenuates memory impairment. Although 4-MU has therapeutic efficacy in rodent models of fibrosis and cancer, it has not been examined in an Alzheimer’s model. Here, we evaluated the impact of long-term 4-MU treatment in the APP/PS1 amyloid mouse model. From three months of age, mice were on either a vehicle or 4-MU–supplemented diet for 70 days or 52 weeks. Short and long-term 4-MU treatment decreased the soluble parenchymal Aβ 1-42 /Aβ 1-40 ratio. Reductions in insoluble amyloid plaque were observed following 52 weeks of treatment. Extended 4-MU administration also reduced PNN intensity and ameliorated spatial memory deficits in APP/PS1 mice. These findings provide support for targeting brain extracellular matrix (ECM) as a therapeutic strategy for AD.
Open Access4-methylumbelliferone attenuates amyloid pathology and learning deficits in the APP/PS1 mouse model
4-Methylumbelliferone (4-MU) inhibits hyaluronic acid (HA) synthesis and is currently approved in Europe for biliary spasm. 4-MU administration reduces perineuronal nets (PNNs), and enzymatic degradation of PNNs in mouse models of Alzheimer’s disease (AD) attenuates memory impairment. Although 4-MU has therapeutic efficacy in rodent models of fibrosis and cancer, it has not been examined in an Alzheimer’s model. Here, we evaluated the impact of long-term 4-MU treatment in the APP/PS1 amyloid mouse model. From three months of age, mice were on either a vehicle or 4-MU–supplemented diet for 70 days or 52 weeks. Short and long-term 4-MU treatment decreased the soluble parenchymal Aβ 1-42 /Aβ 1-40 ratio. Reductions in insoluble amyloid plaque were observed following 52 weeks of treatment. Extended 4-MU administration also reduced PNN intensity and ameliorated spatial memory deficits in APP/PS1 mice. These findings provide support for targeting brain extracellular matrix (ECM) as a therapeutic strategy for AD.
- Open Access
CCL5/CCR5 signaling modulates depression-relevant behavior, neuronal oscillations, and long-term depression of synaptic activity
Major depressive disorder (MDD) is a debilitating disorder, often associated with perseverative thinking and anxiety. Localized reductions in pyramidal cell activity may contribute to associated symptoms, and effective antidepressant treatments typically enhance overall neuronal excitation. CCL5 is a chemokine that has been shown to reduce excitatory-neuronal activity, and is also increased with MDD and conditions that increase MDD risk. Here, we investigate the CCL5/CCR5 axis for its ability to modulate depression-relevant endpoints that are diminished in MDD, including neuronal oscillations, as well as biochemical and behavioral correlates of the disorder. In comparison to wildtype mice, CCR5 knockouts had increased gamma and theta power, and stronger theta/high-gamma phase amplitude coupling during dark-cycle EEG recordings. Compared to strain-matched wildtype mice, CCR5 knockouts also demonstrated reduced anxiety, increased sucrose preference, and improved associative memory. Proteomic analysis of the hippocampus showed that CCR5 knockouts had reduced levels of the GABA receptor alpha-4 subunit, which mediates tonic inhibition and restricts pyramidal cell plasticity. In complementary primary neuronal culture studies, CCL5 diminished GSK-3β activity and impaired NMDA-dependent long-term depression (LTD), a form of plasticity that promotes cognitive flexibility. In addition, CCL5 signaling increased parvalbumin expression in GABAergic neurons through a CCR5-dependent manner. In combination with the ability of CCR5 to restrain gamma oscillation power and LTD, our data raise the possibility that CCL5/CCR5 signaling inhibits neuronal excitation through increased PV+ interneuron activity. Moreover, data are consistent with the possibility that CCR5 antagonists might share the ability of established antidepressants to both increase PC excitation and reduce PC inhibition. Significance Statement: Major depressive disorder (MDD) is a global leading cause of disability, and is associated with increased chemokine activation and inflammation. In this study, we investigate how the CCR5/CCL5 chemokine axis regulates behavioral and cognitive endpoints associated with MDD. This study aims to provide insight to how chemokine signaling underlies mood and behavioral symptoms of neuropsychiatric disorders. We hope this research supports further investigation of CCR5 antagonists for MDD and related mood and anxiety disorders.
Open AccessCCL5/CCR5 signaling modulates depression-relevant behavior, neuronal oscillations, and long-term depression of synaptic activity
Major depressive disorder (MDD) is a debilitating disorder, often associated with perseverative thinking and anxiety. Localized reductions in pyramidal cell activity may contribute to associated symptoms, and effective antidepressant treatments typically enhance overall neuronal excitation. CCL5 is a chemokine that has been shown to reduce excitatory-neuronal activity, and is also increased with MDD and conditions that increase MDD risk. Here, we investigate the CCL5/CCR5 axis for its ability to modulate depression-relevant endpoints that are diminished in MDD, including neuronal oscillations, as well as biochemical and behavioral correlates of the disorder. In comparison to wildtype mice, CCR5 knockouts had increased gamma and theta power, and stronger theta/high-gamma phase amplitude coupling during dark-cycle EEG recordings. Compared to strain-matched wildtype mice, CCR5 knockouts also demonstrated reduced anxiety, increased sucrose preference, and improved associative memory. Proteomic analysis of the hippocampus showed that CCR5 knockouts had reduced levels of the GABA receptor alpha-4 subunit, which mediates tonic inhibition and restricts pyramidal cell plasticity. In complementary primary neuronal culture studies, CCL5 diminished GSK-3β activity and impaired NMDA-dependent long-term depression (LTD), a form of plasticity that promotes cognitive flexibility. In addition, CCL5 signaling increased parvalbumin expression in GABAergic neurons through a CCR5-dependent manner. In combination with the ability of CCR5 to restrain gamma oscillation power and LTD, our data raise the possibility that CCL5/CCR5 signaling inhibits neuronal excitation through increased PV+ interneuron activity. Moreover, data are consistent with the possibility that CCR5 antagonists might share the ability of established antidepressants to both increase PC excitation and reduce PC inhibition. Significance Statement: Major depressive disorder (MDD) is a global leading cause of disability, and is associated with increased chemokine activation and inflammation. In this study, we investigate how the CCR5/CCL5 chemokine axis regulates behavioral and cognitive endpoints associated with MDD. This study aims to provide insight to how chemokine signaling underlies mood and behavioral symptoms of neuropsychiatric disorders. We hope this research supports further investigation of CCR5 antagonists for MDD and related mood and anxiety disorders.
- 2 May 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (9) , 4258-4273
MMP-2/9 inhibition modulates sharp wave abundance, inhibitory proteoglycan sulfation, and fear memory in juvenile zebrafish: relevance to affective disorders
Sharp wave ripple (SWR) events, present in diverse species, spontaneously occur in the hippocampus during quiescent restfulness and slow-wave sleep. SWRs comprise a negative deflection, the sharp wave (SW) event with an often-superimposed ripple (R) and are the neural correlates of memory consolidation and recall. The Anterodorsolateral lobe (ADL) (zebrafish hippocampal homolog) exhibits SW and SWR events, and since SWs initiate SWRs, their abundance typically shows the same directionality. In previous work, we observed matrix metalloproteinase-9 (MMP-9)-dependent effects on depression-relevant behaviors, perineuronal net (PNN) levels, and SWR abundance in the adult rodent hippocampus. Here, we investigate MMP-2/9-dependent effects on biochemical, behavioral, and neurophysiological endpoints in juvenile zebrafish and zebrafish at the transition from the late juvenile period to early adulthood. With MMP-2/9 inhibition, juvenile zebrafish showed reduced SW amplitude and abundance together with increased fear memory retention and decreased sociability. Juvenile zebrafish also showed an increased percentage of longer-duration SW events. Except for a reduction in SW amplitude, these changes were not observed at the transition from late juvenile to early adulthood. These changes were accompanied by increased levels of chondroitin sulfate (CS) proteoglycan 4-O-sulfation, which modulates PNNs and excitatory-to-inhibitory (E/I) balance. Discontinuation of MMP-2/9 inhibition in juvenile zebrafish normalized deficits in ADL SW abundance and sociability. Together, these findings show that MMP-2/9 significantly influences E/I balance and learning and memory during the highly plastic juvenile period. Findings also have relevance to an emerging appreciation of PNN changes that may contribute to altered neuronal oscillations and mood or cognition.
- 2 May 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (9) , 4258-4273
MMP-2/9 inhibition modulates sharp wave abundance, inhibitory proteoglycan sulfation, and fear memory in juvenile zebrafish: relevance to affective disorders
Sharp wave ripple (SWR) events, present in diverse species, spontaneously occur in the hippocampus during quiescent restfulness and slow-wave sleep. SWRs comprise a negative deflection, the sharp wave (SW) event with an often-superimposed ripple (R) and are the neural correlates of memory consolidation and recall. The Anterodorsolateral lobe (ADL) (zebrafish hippocampal homolog) exhibits SW and SWR events, and since SWs initiate SWRs, their abundance typically shows the same directionality. In previous work, we observed matrix metalloproteinase-9 (MMP-9)-dependent effects on depression-relevant behaviors, perineuronal net (PNN) levels, and SWR abundance in the adult rodent hippocampus. Here, we investigate MMP-2/9-dependent effects on biochemical, behavioral, and neurophysiological endpoints in juvenile zebrafish and zebrafish at the transition from the late juvenile period to early adulthood. With MMP-2/9 inhibition, juvenile zebrafish showed reduced SW amplitude and abundance together with increased fear memory retention and decreased sociability. Juvenile zebrafish also showed an increased percentage of longer-duration SW events. Except for a reduction in SW amplitude, these changes were not observed at the transition from late juvenile to early adulthood. These changes were accompanied by increased levels of chondroitin sulfate (CS) proteoglycan 4-O-sulfation, which modulates PNNs and excitatory-to-inhibitory (E/I) balance. Discontinuation of MMP-2/9 inhibition in juvenile zebrafish normalized deficits in ADL SW abundance and sociability. Together, these findings show that MMP-2/9 significantly influences E/I balance and learning and memory during the highly plastic juvenile period. Findings also have relevance to an emerging appreciation of PNN changes that may contribute to altered neuronal oscillations and mood or cognition.
- 3 March 2025
- Published by Wiley in Journal of Neurochemistry
- Vol. 169 (3) , e70032
Preface to the Special Issue “Matrix Metalloproteinases in Health and Disease”
This preface introduces a collection of new work focused on matrix metalloproteinases (MMPs) and select MMP substrates in the nervous system. Discovered over 60 years ago during the study of collagen degradation during tadpole tail metamorphosis by Gross and Lapiere, MMPs are now known to play critical roles in adaptive and non‐adaptive physiological processes in varied species. Though early studies focused predominantly on their role in inflammation, wound healing, and angiogenesis, work during the last 20 years has expanded to include an abundance of studies related to MMPs and their substrates in brain disease and plasticity. Particularly novel and intriguing studies are numerous and include those related to the role of MMPs in mood and memory, as well as studies of select MMP substrates in critical period closure. The manuscripts herein include a review of MMP‐9, an MMP that is released from resident cells of the brain, including neurons and microglia, as well as a comprehensive review of perineuronal nets (PNNs), which are composed of MMP substrates including brevican. Additional manuscripts focus on fragile X messenger ribonucleoprotein 1 product (FMRP) in the translational regulation of aggrecan, an important PNN component, as well as manuscripts showing PNN chondroitin sulfate‐glycosaminoglycan compositional changes in a mouse model of tauopathy, a novel localization of PNN‐like structures in the enteric nervous system, a mechanism by which MMP‐2 could contribute to the disruption of the blood‐brain barrier, and differential effects of a sirtuin agonist on glial and neuronal MMP release.
- 3 March 2025
- Published by Wiley in Journal of Neurochemistry
- Vol. 169 (3) , e70032
Preface to the Special Issue “Matrix Metalloproteinases in Health and Disease”
This preface introduces a collection of new work focused on matrix metalloproteinases (MMPs) and select MMP substrates in the nervous system. Discovered over 60 years ago during the study of collagen degradation during tadpole tail metamorphosis by Gross and Lapiere, MMPs are now known to play critical roles in adaptive and non‐adaptive physiological processes in varied species. Though early studies focused predominantly on their role in inflammation, wound healing, and angiogenesis, work during the last 20 years has expanded to include an abundance of studies related to MMPs and their substrates in brain disease and plasticity. Particularly novel and intriguing studies are numerous and include those related to the role of MMPs in mood and memory, as well as studies of select MMP substrates in critical period closure. The manuscripts herein include a review of MMP‐9, an MMP that is released from resident cells of the brain, including neurons and microglia, as well as a comprehensive review of perineuronal nets (PNNs), which are composed of MMP substrates including brevican. Additional manuscripts focus on fragile X messenger ribonucleoprotein 1 product (FMRP) in the translational regulation of aggrecan, an important PNN component, as well as manuscripts showing PNN chondroitin sulfate‐glycosaminoglycan compositional changes in a mouse model of tauopathy, a novel localization of PNN‐like structures in the enteric nervous system, a mechanism by which MMP‐2 could contribute to the disruption of the blood‐brain barrier, and differential effects of a sirtuin agonist on glial and neuronal MMP release.
- Open Access
MMP-2/9 inhibition modulates sharp wave abundance, inhibitory proteoglycan sulfation, and fear memory in juvenile zebrafish: relevance to affective disorders
Sharp wave ripple (SWR) events, present in diverse species, spontaneously occur in the hippocampus during quiescent restfulness and slow-wave sleep. SWRs comprise a negative deflection, the sharp wave (SW) event with an often-superimposed ripple (R) and are the neural correlates of memory consolidation and recall. The Anterodorsolateral lobe (ADL) (zebrafish hippocampal homologue) exhibits SW and SWR events, and since SWs initiate SWRs, their abundance typically shows the same directionality. In previous work, we observed matrix metalloproteinase-9 (MMP-9)-dependent effects on depression-relevant behaviors, perineuronal net (PNN) levels, and SWR abundance in the adult rodent hippocampus. Here, we investigate MMP-2/9-dependent effects on biochemical, behavioral, and neurophysiological endpoints in juvenile zebrafish and zebrafish at the transition from the late juvenile period to early adulthood. With MMP-2/9 inhibition, juvenile zebrafish showed reduced SW amplitude and abundance together with increased fear memory retention and reduced sociability. Juvenile zebrafish also showed an increased percentage of longer-duration SW events. Except for a reduction in SW amplitude, these changes were not observed at the transition from late juvenile to early adulthood. These changes were accompanied by increased levels of chondroitin sulfate (CS) proteoglycan 4- O -sulfation, which modulates PNNs and excitatory-to-inhibitory (E/I) balance. Discontinuation of MMP-2/9 inhibition in juvenile zebrafish normalized deficits in ADL SW abundance and sociability. Together, these findings show that MMP-2/9 significantly influences E/I balance and learning and memory during the highly plastic juvenile period in zebrafish. Findings also have relevance to an emerging appreciation of PNN changes that may contribute to altered neuronal oscillations and mood or cognition.
Open AccessMMP-2/9 inhibition modulates sharp wave abundance, inhibitory proteoglycan sulfation, and fear memory in juvenile zebrafish: relevance to affective disorders
Sharp wave ripple (SWR) events, present in diverse species, spontaneously occur in the hippocampus during quiescent restfulness and slow-wave sleep. SWRs comprise a negative deflection, the sharp wave (SW) event with an often-superimposed ripple (R) and are the neural correlates of memory consolidation and recall. The Anterodorsolateral lobe (ADL) (zebrafish hippocampal homologue) exhibits SW and SWR events, and since SWs initiate SWRs, their abundance typically shows the same directionality. In previous work, we observed matrix metalloproteinase-9 (MMP-9)-dependent effects on depression-relevant behaviors, perineuronal net (PNN) levels, and SWR abundance in the adult rodent hippocampus. Here, we investigate MMP-2/9-dependent effects on biochemical, behavioral, and neurophysiological endpoints in juvenile zebrafish and zebrafish at the transition from the late juvenile period to early adulthood. With MMP-2/9 inhibition, juvenile zebrafish showed reduced SW amplitude and abundance together with increased fear memory retention and reduced sociability. Juvenile zebrafish also showed an increased percentage of longer-duration SW events. Except for a reduction in SW amplitude, these changes were not observed at the transition from late juvenile to early adulthood. These changes were accompanied by increased levels of chondroitin sulfate (CS) proteoglycan 4- O -sulfation, which modulates PNNs and excitatory-to-inhibitory (E/I) balance. Discontinuation of MMP-2/9 inhibition in juvenile zebrafish normalized deficits in ADL SW abundance and sociability. Together, these findings show that MMP-2/9 significantly influences E/I balance and learning and memory during the highly plastic juvenile period in zebrafish. Findings also have relevance to an emerging appreciation of PNN changes that may contribute to altered neuronal oscillations and mood or cognition.
- 16 October 2024
- Published by Wiley in European Journal of Neuroscience
- Vol. 60 (10) , 6490-6508
Pramipexole, a D3 receptor agonist, increases cortical gamma power and biochemical correlates of cortical excitation; implications for mood disorders
Major depressive disorder (MDD) has been associated with deficits in working memory as well as underlying gamma oscillation power. Consistent with this, overall reductions in cortical excitation have also been described with MDD. In previous work, we have demonstrated that the monoamine reuptake inhibitor venlafaxine increases gamma oscillation power in ex vivo hippocampal slices and that this is associated with concomitant increases in pyramidal arbour and reduced levels of plasticity‐restricting perineuronal nets (PNNs). In the present study, we have examined the effects of chronic treatment with pramipexole (PPX), a D3 dopamine receptor agonist, for its effects on gamma oscillation power as measured by in vivo electroencephalography (EEG) recordings in female BALB/c and C57Bl6 mice. We observe a modest but significant increase in 20–50 Hz gamma power with PPX in both strains. Additionally, biochemical analysis of prefrontal cortex lysates from PPX‐treated BALB/c mice shows a number of changes that could contribute to, or follow from, increased pyramidal excitability and/or gamma power. PPX‐associated changes include reduced levels of specific PNN components as well as tissue inhibitor of matrix metalloproteases‐1 (TIMP‐1), which inhibits long‐term potentiation of synaptic transmission. Consistent with its effects on gamma power, PNN proteins and TIMP‐1, chronic PPX treatment also improves working memory and reduces anhedonia. Together these results add to an emerging literature linking extracellular matrix and/or gamma oscillation power to both mood and cognition.
- 16 October 2024
- Published by Wiley in European Journal of Neuroscience
- Vol. 60 (10) , 6490-6508
Pramipexole, a D3 receptor agonist, increases cortical gamma power and biochemical correlates of cortical excitation; implications for mood disorders
Major depressive disorder (MDD) has been associated with deficits in working memory as well as underlying gamma oscillation power. Consistent with this, overall reductions in cortical excitation have also been described with MDD. In previous work, we have demonstrated that the monoamine reuptake inhibitor venlafaxine increases gamma oscillation power in ex vivo hippocampal slices and that this is associated with concomitant increases in pyramidal arbour and reduced levels of plasticity‐restricting perineuronal nets (PNNs). In the present study, we have examined the effects of chronic treatment with pramipexole (PPX), a D3 dopamine receptor agonist, for its effects on gamma oscillation power as measured by in vivo electroencephalography (EEG) recordings in female BALB/c and C57Bl6 mice. We observe a modest but significant increase in 20–50 Hz gamma power with PPX in both strains. Additionally, biochemical analysis of prefrontal cortex lysates from PPX‐treated BALB/c mice shows a number of changes that could contribute to, or follow from, increased pyramidal excitability and/or gamma power. PPX‐associated changes include reduced levels of specific PNN components as well as tissue inhibitor of matrix metalloproteases‐1 (TIMP‐1), which inhibits long‐term potentiation of synaptic transmission. Consistent with its effects on gamma power, PNN proteins and TIMP‐1, chronic PPX treatment also improves working memory and reduces anhedonia. Together these results add to an emerging literature linking extracellular matrix and/or gamma oscillation power to both mood and cognition.
- Open Access
- 6 June 2024
- Published by Wiley in European Journal of Neuroscience
- Vol. 60 (3) , 4303-4316
Short‐term exposure to HIV Tat induces glial activation and changes in perineuronal nets
Despite widespread use of combination antiretroviral therapy (cART), there remains a subset of individuals who display cognitive impairment broadly known as HIV‐associated neurocognitive disorder (HAND). Interestingly, HIV‐infected cells continuously release the HIV‐1 protein Tat even in the presence of cART. Persistent exposure to Tat is proposed to increase both neuroinflammation and neurotoxicity. In vitro evidence shows that matrix metalloproteinases (MMPs) are among the neuroinflammatory molecules induced by Tat, which are known to disrupt specialized neuronal extracellular matrix structures called perineuronal nets (PNNs). PNNs predominantly surround parvalbumin interneurons and help to buffer these cells from oxidant stress and to independently increase their excitability. In order to better understand the link between short‐term exposure to Tat, neuroinflammation, and PNNs, we explored the direct effects of Tat on glial cells and neurons. Herein, we report that in mixed glial cultures, Tat directly increases the expression of proinflammatory molecules, including MMP‐9. Moreover, direct injection of Tat protein into mouse hippocampus increases the expression of astrocyte and microglia markers as well as MMP‐9. The number of PNNs is decreased following Tat exposure, followed later by decreased numbers of hippocampal parvalbumin‐expressing neurons. In older mice, Tat induced significant increases in the gene expression of proinflammatory molecules including markers of gliosis, MMPs and complement system proteins. Taken together, these data support a direct effect of Tat on glial‐derived MMP expression subsequently affecting PNNs and neuronal health, with older mice more susceptible to Tat‐induced inflammation.
- 6 June 2024
- Published by Wiley in European Journal of Neuroscience
- Vol. 60 (3) , 4303-4316
Open AccessShort‐term exposure to HIV Tat induces glial activation and changes in perineuronal nets
Despite widespread use of combination antiretroviral therapy (cART), there remains a subset of individuals who display cognitive impairment broadly known as HIV‐associated neurocognitive disorder (HAND). Interestingly, HIV‐infected cells continuously release the HIV‐1 protein Tat even in the presence of cART. Persistent exposure to Tat is proposed to increase both neuroinflammation and neurotoxicity. In vitro evidence shows that matrix metalloproteinases (MMPs) are among the neuroinflammatory molecules induced by Tat, which are known to disrupt specialized neuronal extracellular matrix structures called perineuronal nets (PNNs). PNNs predominantly surround parvalbumin interneurons and help to buffer these cells from oxidant stress and to independently increase their excitability. In order to better understand the link between short‐term exposure to Tat, neuroinflammation, and PNNs, we explored the direct effects of Tat on glial cells and neurons. Herein, we report that in mixed glial cultures, Tat directly increases the expression of proinflammatory molecules, including MMP‐9. Moreover, direct injection of Tat protein into mouse hippocampus increases the expression of astrocyte and microglia markers as well as MMP‐9. The number of PNNs is decreased following Tat exposure, followed later by decreased numbers of hippocampal parvalbumin‐expressing neurons. In older mice, Tat induced significant increases in the gene expression of proinflammatory molecules including markers of gliosis, MMPs and complement system proteins. Taken together, these data support a direct effect of Tat on glial‐derived MMP expression subsequently affecting PNNs and neuronal health, with older mice more susceptible to Tat‐induced inflammation.